Abstract 154P
Background
Uveal melanoma (UM), the most prevalent adult primary intraocular malignancy, frequently progresses to incurable metastatic disease with fatal outcomes. Unlike cutaneous melanoma, metastatic UM demonstrates limited response to PD-1 checkpoint inhibition, leading to a persistently poor prognosis. We previously reported significant expression of the inhibitory immune checkpoint molecule, LAG3, on CD8+ cytotoxic Tcells in metastatic UM. Consequently, we initiated a clinical trial to assess the therapeutic efficacy of dual PD-1/LAG3 blockade in metastatic UM with nivolumab/relatlimab (Nivo/Rela).
Methods
Single-cell RNA and TCR sequencing of circulating CD3+ Tcells from 27 UM patients receiving Nivo/Rela was performed at pre-treatment baseline, mid-treatment (n=5), and end-of-treatment (EOT), including a final cohort of 2 partial response (PR), 12 stable disease (SD), and 13 progressive disease (PD) patients.
Results
Several immune and transcriptomic features were identified associated with treatment response and resistance. PR individuals exhibited elevated levels of circulating CD8+ effector/memory Tcells at end-of-treatment. Transcriptomic profiling revealed differentially expressed genes (DEGs) in CD8+ Tcells linked with treatment response, with PR/SD patients showing upregulation of LAG3, JUN, and CCL4 at baseline compared to the PD cohort. Comparing EOT to baseline samples, the PD cohort upregulated FOS and JUN, whereas these DEGs were mainly downregulated in SD patients. TCR repertoire analysis revealed increased clonality of circulating Tcells in PR patients, while the SD cohort with mid-treatment timepoints (n=4) displayed TCR repertoire expansion during treatment with repertoire contraction by EOT. TCR epitope specificity analysis revealing anti-melanoma Tcell clones expressing LAG3 across the patient cohort, with enhanced anti-melanoma TCR clonality observed in the PR cohort.
Conclusions
Our study delineates transcriptional and clonality alterations in circulating CD8+ Tcells associated with response and identifies potential mechanisms and biomarkers related to the immunotherapeutic efficacy of Nivo/Rela in UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bristol Myers Squibb.
Disclosure
Z. Correa, J.W. Harbour: Financial Interests, Personal and Institutional, Other: Castle Biosciences. J. Lutzky: Financial Interests, Personal, Other, reviewed grant applications for department of defense: general dynamics; Financial Interests, Personal, Advisory Board: Regeneron, Immunocore; Financial Interests, Personal, Other, safety monitoring committee: Agenus, Celldex; Financial Interests, Institutional, Research Grant, Funding for institutional trial: BMS; Financial Interests, Institutional, Local PI: Trisalus, Takeda, Vyriad, Tango, Immunocore, Replimune, Oncohost, Dragonfly, Iovance, Ideaya. All other authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08